Fierce Biotech January 24, 2024
After announcing last September that it had logged the first successful implantation of its pea-sized neurostimulator for depression, Motif Neurotech has raised $18.75 million in venture capital funds to continue its development with a full clinical study.
Described as a “brain pacemaker,” the startup’s minimally invasive Motif DOT implant is aimed at severe, treatment-resistant depression. Measuring less than one centimeter across, it does not contain a battery or connect to leads. Instead, a separate magnetic coil in a wearable headset is used to wirelessly power the system, which is placed in a burr hole in the skull and does not come into contact with the brain.
The company plans to build its approach into an at-home therapy, with the device...
Today's Sponsors
Today's Sponsor